Fasting in diabetes treatment (FIT) trial: study protocol for a randomised, controlled, assessor-blinded intervention trial on the effects of intermittent use of a fasting-mimicking diet in patients with type 2 diabetes
Open Access
- 24 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Endocrine Disorders
- Vol. 20 (1), 1-11
- https://doi.org/10.1186/s12902-020-00576-7
Abstract
Background Caloric restriction is an effective way to treat Type 2 diabetes (T2D). However, chronic and severe restriction of food intake is difficult to sustain and is known to promote slower metabolism. Intermittent and frequent fasting can exert similar metabolic effects, but may be even more challenging for most patients. A fasting-mimicking diet (FMD) is low in calories, sugars and proteins, but includes relatively high levels of plant based complex carbohydrates and healthy fats. The metabolic effects of such a diet mimic the benefits of water-only fasting. The effects of a FMD applied periodically in T2D patients are still unknown. The Fasting In diabetes Treatment (FIT) trial was designed to determine the effect of intermittent use (5 consecutive days a month during a year) of a FMD in T2D patients on metabolic parameters and T2D medication use compared to usual care. Methods One hundred T2D patients from general practices in the Netherlands with a BMI >= 27 kg/m(2), treated with lifestyle advice only or lifestyle advice plus metformin, will be randomised to receive the FMD plus usual care or usual care only. Primary outcomes are HbA1c and T2D medication dosage. Secondary outcomes are anthropometrics, blood pressure, plasma lipid profiles, quality of life, treatment satisfaction, metabolomics, microbiome composition, MRI data including cardiac function, fat distribution and ectopic fat storage, cost-effectiveness, and feasibility in clinical practice. Discussion This study will establish whether monthly 5-day cycles of a FMD during a year improve metabolic parameters and/or reduce the need for medication in T2D. Furthermore, additional health benefits and the feasibility in clinical practice will be measured and a cost-effectiveness evaluation will be performed.This publication has 35 references indexed in Scilit:
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82Diabetologia, 2013
- Type 2 DiabetesDiabetes Care, 2013
- Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country studyQuality of Life Research, 2012
- Health Benefits of Gastric Bypass Surgery After 6 YearsJAMA, 2012
- Gene-Environment Interactions in the Development of Type 2 Diabetes: Recent Progress and Continuing ChallengesAnnual Review of Nutrition, 2012
- Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerolDiabetologia, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activityJournal of Clinical Epidemiology, 2003
- Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intakeProceedings of the National Academy of Sciences of the United States of America, 2003
- Measures of Psychological Well‐being and Treatment Satisfaction Developed from the Responses of People with Tablet‐treated DiabetesDiabetic Medicine, 1990